McClarren Financial Advisors Inc. Purchases 4,643 Shares of Pfizer Inc. (NYSE:PFE)

McClarren Financial Advisors Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 2,381.0% during the 3rd quarter, Holdings Channel reports. The firm owned 4,838 shares of the biopharmaceutical company’s stock after acquiring an additional 4,643 shares during the period. McClarren Financial Advisors Inc.’s holdings in Pfizer were worth $151,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in PFE. Los Angeles Capital Management LLC boosted its holdings in Pfizer by 59.6% in the first quarter. Los Angeles Capital Management LLC now owns 47,663 shares of the biopharmaceutical company’s stock valued at $1,323,000 after acquiring an additional 17,799 shares in the last quarter. Douglas Lane & Associates LLC lifted its position in Pfizer by 1.5% during the first quarter. Douglas Lane & Associates LLC now owns 46,677 shares of the biopharmaceutical company’s stock valued at $1,295,000 after buying an additional 704 shares during the period. RDA Financial Network lifted its position in Pfizer by 8.0% during the first quarter. RDA Financial Network now owns 12,938 shares of the biopharmaceutical company’s stock valued at $359,000 after buying an additional 960 shares during the period. Game Plan Financial Advisors LLC lifted its position in Pfizer by 1,671.4% during the first quarter. Game Plan Financial Advisors LLC now owns 3,100 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 2,925 shares during the period. Finally, Northwest Investment Counselors LLC purchased a new position in Pfizer during the first quarter valued at $89,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PFE shares. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.05 during trading hours on Friday, reaching $29.22. 24,244,872 shares of the stock traded hands, compared to its average volume of 37,106,250. The company has a 50 day moving average price of $29.07 and a 200 day moving average price of $28.44. The firm has a market capitalization of $165.58 billion, a price-to-earnings ratio of -487.00, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.67 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.75%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.